Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Susan SwindellsUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0001-5826-6037
Amita GuptaDivision of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0001-7036-2718
N Sarita ShahRollins School of Public Health, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-6069-0857
Michael HughesHarvard TH Chan, School of Public Health, Harvard University, Boston, Massachusetts, USA.
Soyeon KimHarvard TH Chan, School of Public Health, Harvard University, Boston, Massachusetts, USA.ORCID 0000-0002-4776-6092
Greg J FoxFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Mark HarringtonTreatment Action Group, New York, New York, USA.
Richard E ChaissonDivision of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Anneke C HesselingDesmond Tutu TB Centre, Stellenbosch University, Stellenbosch, South Africa.
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU Y18 SupplementUM1AI069456 · NIAID · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2012 to 2026
$29.4M
Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5M
Aurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1M
Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8M
Mentoring Multidisciplinary Patient-Oriented Research in TB, HIV, and Global HealthK24AI165099 · NIAID · EMORY UNIVERSITY · PI Nippie Sarita Shah · 2023 to 2026
$781k
ACTGAdvancing Clinical Therapeutics GloballyAurum Institute Clinical Trials UnitEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentGeorgia Tuberculosis Research Advancement Center P30AI168386International Maternal Pediatric Adolescent AIDS Clinical Trials NetworkJohns Hopkins University Baltimore-India Clinical Trials Unit UM1AI154463National Institute of Allergy and Infectious DiseasesNIAID NIH HHS K24 AI165099NIAID NIH HHS P30 AI168386NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069456NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069521NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI106716NIAID NIH HHS UM1 AI154463NICHD NIH HHS HHSN275201800001INICHD NIH HHS UM1AI069465NIH HHSNIH HHS K24AI165099NIH HHS UM1AI068616NIH HHS UM1AI068632NIH HHS UM1AI068634NIH HHS UM1AI068636NIH HHS UM1AI106701NIH HHS UM1AI106716NIMH NIH HHS
6 · The paper itself
Abstract
Multidrug-resistant tuberculosis (MDR-TB) remains a global health threat and accounts for a quarter of deaths due to antimicrobial resistance. Individuals infected with MDR-TB are at risk of progressing to TB disease. Treatment of drug-resistant TB infection to prevent progression to disease and avert the associated morbidity and mortality is a global priority. Randomized evidence to inform TB preventive treatment (TPT) guidelines has been lacking. Two recently completed trials provide the first randomized evidence that treatment of household contacts exposed to people with MDR-TB with daily levofloxacin for 6 months is safe and efficacious in preventing TB. Based on these results, the World Health Organization updated its TPT guidelines to make a strong recommendation for use of levofloxacin for 6 months in MDR-TB exposed contacts. Novel, shorter regimens in development will usher in a new era for the treatment of MDR-TB infection if shown to be safe and efficacious.
Indexed as
Antitubercular AgentsLevofloxacinTuberculosis, Multidrug-ResistantGlobal HealthHumansMycobacterium tuberculosisPractice Guidelines as TopicRandomized Controlled Trials as TopicWorld Health OrganizationAntitubercular AgentsLevofloxacinbedaquilinedelamanidlevofloxacinpreventive treatmenttuberculosis infection
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era. · full record | Socratic